2 results
Approved WMOCompleted
Objective: to provide an answer to the following question: in patients with AD, does treatment with a ChEI improve cerebral autoregulation?
Approved WMOCompleted
Primary Objectives:• Determine the safety and tolerability of CC-122 administered in combination with obinutuzumab.• Determine the non-tolerated dose (NTD), maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of CC-122 administered in…